Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDIZEM vs CADUET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Diltiazem inhibits calcium influx into cardiac and vascular smooth muscle cells during depolarization by binding to L-type calcium channels. This results in coronary vasodilation, decreased myocardial oxygen demand, and negative chronotropic and inotropic effects.
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.
Angina pectoris (chronic stable, vasospastic),Atrial fibrillation or atrial flutter (rate control),Hypertension
Hypertension,Coronary artery disease,Hyperlipidemia (as adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels, and to increase HDL-C),Prevention of cardiovascular events in patients with multiple risk factors
Oral: 30-120 mg three to four times daily; extended-release: 120-360 mg once daily. IV: Initial 0.25 mg/kg (max 25 mg) bolus over 2 minutes, may repeat in 15 minutes (0.35 mg/kg); maintenance: 5-15 mg/hour continuous infusion.
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
Terminal elimination half-life is 3.0-4.5 hours in healthy adults; may be prolonged to 7-9 hours in elderly, hepatic impairment, or renal impairment; clinically relevant for dosing frequency.
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-Co A reductase inhibition) is ~20-30 h.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism; metabolites: desacetyl diltiazem (active, 40-50% potency), N-demethylated, and deacetylated forms.
Amlodipine: Extensively metabolized in the liver via CYP3A4 to inactive metabolites. Atorvastatin: Metabolized in the liver primarily by CYP3A4 to active ortho- and para-hydroxylated metabolites.
Primarily hepatic metabolism with extensive first-pass effect; approximately 2-4% excreted unchanged in urine; fecal excretion accounts for about 65% of dose as metabolites; renal excretion accounts for about 35% of dose as metabolites.
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
77-87% bound to plasma proteins, primarily albumin.
Amlodipine: ~93% bound to plasma proteins. Atorvastatin: ≥98% bound to plasma proteins (mainly albumin).
3-5 L/kg; large Vd indicates extensive tissue binding and distribution.
Amlodipine: Vd ~21 L/kg (large, indicating extensive tissue distribution). Atorvastatin: Vd ~6.2 L/kg (moderately large, suggesting distribution into tissues).
Oral: 40-50% due to significant first-pass metabolism (range 30-60% across individuals); IV: 100%.
Oral: amlodipine 64-90%; atorvastatin ~14% (low due to first-pass metabolism); food reduces rate but not extent of absorption.
No specific dose adjustment for renal impairment; use with caution in severe renal dysfunction (Cr Cl <30 m L/min) with close monitoring of heart rate and blood pressure.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), use atorvastatin with caution; maximum atorvastatin dose is 20 mg daily. Amlodipine is not dialyzable.
Child-Pugh Class A: No adjustment. Class B: Reduce total daily dose by 25-50%. Class C: Avoid use; if necessary, consider further dose reduction with careful monitoring.
Contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. For Child-Pugh Class A or B hepatic impairment: atorvastatin dose should be reduced; maximum atorvastatin dose is 20 mg daily. Amlodipine clearance is decreased; initial amlodipine dose should be 2.5 mg daily. No data for Child-Pugh Class C; use contraindicated.
Oral: 1.5-2 mg/kg/day divided every 6-8 hours, maximum 3.5 mg/kg/day. Extended-release not recommended in children. IV: Use only with caution; dosing not well established; typical initial bolus 0.1-0.3 mg/kg over 2 minutes, maximum 10 mg; infusion 0.5-5 mcg/kg/min.
Not recommended for pediatric patients. Safety and efficacy in children <10 years have not been established. For patients 10-17 years with heterozygous familial hypercholesterolemia, atorvastatin monotherapy is used; CADUET is not indicated.
Start at lower end of dosing range: oral immediate-release 30 mg three times daily; extended-release 120 mg once daily. Increase slowly. IV: Lower initial bolus (0.15-0.2 mg/kg) and infusion rates (2-5 mg/hour). Monitor for hypotension and bradycardia.
Elderly patients (≥65 years) may have increased sensitivity to amlodipine; start at the lower end of dosing range (2.5 mg amlodipine component). Atorvastatin dose adjustment not required based on age alone. Monitor for hypotension and other adverse effects.
There is no FDA black box warning for CARDIZEM (diltiazem).
HMG-Co A reductase inhibitors (statins) can cause fetal harm; use in pregnant women is contraindicated. Caduet contains atorvastatin; therefore, it is contraindicated in pregnant women.
Symptomatic hypotension,Bradycardia or heart block (especially in sick sinus syndrome or AV block without pacemaker),Worsening heart failure in patients with reduced ventricular function,Hepatic injury (rare but elevated liver enzymes reported),Concomitant use with beta-blockers may increase risk of bradycardia and heart failure,Digitalis toxicity risk increased when used with digoxin,May exacerbate myasthenia gravis,Acute generalized exanthematous pustulosis (AGEP) and other severe cutaneous reactions,Gradual withdrawal recommended for chronic therapy to avoid angina exacerbation,May lower blood pressure, use with caution in patients with hypotension,Use in renal impairment: monitor carefully
Myopathy/Rhabdomyolysis: Risk increased with higher doses, age >65, renal impairment, hypothyroidism, and concurrent use of CYP3A4 inhibitors or other drugs that cause myopathy.,Hepatic effects: Elevated liver enzymes; perform liver function tests before initiation and as clinically indicated.,Fetal toxicity: May cause fetal harm; advise females of reproductive age to use effective contraception.,Peripheral edema: More common with higher doses of amlodipine, especially in females.,Hypotension: In patients with severe aortic stenosis.
Hypersensitivity to diltiazem or any component,Sick sinus syndrome (except with functioning ventricular pacemaker),Second- or third-degree AV block (except with functioning pacemaker),Severe hypotension (systolic < 90 mm Hg),Acute myocardial infarction with pulmonary congestion,Atrial fibrillation or flutter associated with accessory bypass tract (e.g., WPW syndrome; risk of ventricular tachycardia or fibrillation),Cardiogenic shock,Concurrent use with ivabradine,Lactation (due to potential adverse effects in infants)
Active liver disease or unexplained persistent elevations of hepatic transaminases,Pregnancy,Breastfeeding (due to potential for serious adverse reactions in nursing infants),Hypersensitivity to amlodipine, atorvastatin, or any component of the formulation
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase diltiazem levels, leading to toxicity. High-fat meals may increase absorption of some extended-release formulations; take with consistent meals. Alcohol may increase the risk of hypotension and dizziness. Maintain adequate hydration and avoid excessive salt intake to control blood pressure.
Avoid grapefruit and grapefruit juice as they increase atorvastatin plasma concentrations and risk of adverse effects. No significant food interactions with amlodipine.
No adequate studies in pregnant women. In animal studies, diltiazem (Cardizem) has been shown to cause skeletal abnormalities and increased fetal mortality at doses 5-10 times the maximum recommended human dose. Based on animal data and human experience with calcium channel blockers, risk cannot be ruled out. Use only if potential benefit justifies risk to fetus. Category C.
FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-Co A reductase inhibitors are associated with fetal abnormalities, including skeletal and CNS defects. First trimester: Atorvastatin is contraindicated; risk of congenital anomalies. Second/third trimester: Avoid exposure; potential for fetal toxicity. Effective contraception required for women of childbearing potential.
Diltiazem is excreted in human milk. A study reported a milk-to-plasma (M/P) ratio of approximately 0.9. The estimated infant dose is 1-2% of maternal weight-adjusted dose. Caution is advised; consider waiting 3-4 hours after dose before breastfeeding to minimize exposure.
Excreted in human milk: Amlodipine: present in low levels (M/P ratio approximately 1.0); atorvastatin: unknown. Due to potential for serious adverse reactions in nursing infants (e.g., skeletal muscle toxicity from statins), breastfeeding is contraindicated during therapy. Alternative agents preferred.
Increased plasma volume and altered protein binding in pregnancy may reduce diltiazem concentrations; consider dose titration based on clinical response. No specific dose adjustment established; monitor therapeutic effect.
Contraindicated during pregnancy; therefore, no dosing adjustments recommended. Discontinue therapy immediately if pregnancy is suspected or confirmed. Pharmacokinetic changes during pregnancy may alter drug metabolism, but no dose adjustments are justified due to teratogenic risk.
Cardizem (diltiazem) is a non-dihydropyridine calcium channel blocker used for hypertension, angina, and atrial fibrillation/atrial flutter. It is contraindicated with IV beta-blockers due to risk of bradycardia and heart block. In AF, use IV form for rate control but avoid in WPW due to risk of ventricular pre-excitation. Diltiazem is metabolized by CYP3A4; caution with strong inhibitors like clarithromycin or grapefruit juice. For hypertension, start at 30 mg TID or extended-release once daily. Monitor heart rate and PR interval; avoid in sick sinus syndrome or second/third-degree AV block without pacemaker.
CADUET is a fixed-dose combination of amlodipine (a calcium channel blocker) and atorvastatin (a statin) used for hypertension and dyslipidemia. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) due to increased statin exposure and risk of myopathy. Monitor liver enzymes before and during therapy, and for muscle symptoms. Use with caution in patients with severe renal impairment. Avoid grapefruit juice as it increases atorvastatin levels.
Take this medication exactly as prescribed; do not crush or chew extended-release capsules.,Avoid grapefruit and grapefruit juice while taking this medication.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.,Do not stop taking this medication abruptly, as it may worsen your condition.,Common side effects include dizziness, headache, and swelling in the ankles/feet; contact your doctor if you experience slow heartbeat, shortness of breath, or fainting.,This medication may cause dizziness or lightheadedness; avoid driving or operating machinery until you know how it affects you.
Take this medication once daily at the same time, with or without food.,Avoid grapefruit and grapefruit juice while taking this medication.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Notify your doctor if you become pregnant, plan to become pregnant, or are breastfeeding.,Do not stop taking this medication without consulting your doctor, even if you feel well.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDIZEM vs CADUET, answered by our medical review team.
CARDIZEM is a Calcium Channel Blocker that works by Diltiazem inhibits calcium influx into cardiac and vascular smooth muscle cells during depolarization by binding to L-type calcium channels. This results in coronary vasodilation, decreased myocardial oxygen demand, and negative chronotropic and inotropic effects.. CADUET is a Calcium Channel Blocker + HMG-CoA Reductase Inhibitor that works by Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-Co A reductase inhibitor that competitively inhibits the conversion of HMG-Co A to mevalonate, reducing cholesterol synthesis in the liver.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDIZEM and CADUET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDIZEM is: Oral: 30-120 mg three to four times daily; extended-release: 120-360 mg once daily. IV: Initial 0.25 mg/kg (max 25 mg) bolus over 2 minutes, may repeat in 15 minutes (0.35 mg/kg); maintenance: 5-15 mg/hour continuous infusion.. The standard adult dose of CADUET is: CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDIZEM and CADUET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDIZEM is classified as Category C. No adequate studies in pregnant women. In animal studies, diltiazem (Cardizem) has been shown to cause skeletal abnormalities and increased fetal mortality at doses 5-10 times the . CADUET is classified as Category C. FDA Pregnancy Category X. Amlodipine: No evidence of teratogenicity in animal studies, but limited human data; atorvastatin: contraindicated in pregnancy as HMG-CoA reductase inhib. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.